Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RCUS Stock Forecast

Arcus Biosciences stock forecast is as follows: an average price target of $33.00 (represents a 110.19% upside from RCUS’s last price of $15.70) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

RCUS Price Target

The average price target for Arcus Biosciences (RCUS) is $33.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $20.00. This represents a potential 110.19% upside from RCUS's last price of $15.70.

RCUS Analyst Ratings

Buy

According to 7 Wall Street analysts, Arcus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RCUS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arcus Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	Yigal Nochomovitz	Citigroup	$46.00	$17.41	164.14%	192.99%
Oct 21, 2024	Emily Bodnar	H.C. Wainwright	$20.00	$18.44	8.46%	27.39%
Oct 08, 2024	Judah Frommer	Morgan Stanley	$35.00	$18.08	93.58%	122.93%
Oct 08, 2024	Eva Fortea Verdejo	Wells Fargo	$29.00	$18.08	60.40%	84.71%
Aug 09, 2024	Jason Zemansky	Bank of America Securities	$23.00	$13.69	68.01%	46.50%
Jul 08, 2024	Peter Lawson	Barclays	$25.00	$14.00	78.57%	59.24%
Jun 24, 2024	Asthika Goonewardene	Truist Financial	$44.00	$16.45	167.48%	180.25%
Jun 04, 2024	Peter Lawson	Barclays	$35.00	$16.15	116.72%	122.93%
Dec 20, 2022	-	Citigroup	$42.00	$20.66	103.29%	167.52%
Nov 23, 2022	-	Citigroup	$37.00	$27.00	37.04%	135.67%

Row per page

Go to

The latest Arcus Biosciences stock forecast, released on Oct 24, 2024 by Yigal Nochomovitz from Citigroup, set a price target of $46.00, which represents a 164.14% increase from the stock price at the time of the forecast ($17.41), and a 192.99% increase from RCUS last price ($15.70).

Arcus Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	2	4	8
Avg Price Target	$33.00	$32.50	$32.13
Last Closing Price	$15.70	$15.70	$15.70
Upside/Downside	110.19%	107.01%	104.65%

In the current month, the average price target of Arcus Biosciences stock is $33.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 110.19% increase as opposed to Arcus Biosciences's last price of $15.70. This month's average price target is up 1.54% compared to last quarter, and up 2.71% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	Citigroup	Buy	Buy	Hold
Oct 21, 2024	Wells Fargo	Neutral	Neutral	Hold
Oct 21, 2024	Wedbush	Underperform	Underperform	Hold
Oct 21, 2024	H.C. Wainwright	-	Neutral	Initialise
Oct 08, 2024	Morgan Stanley	Underperform	Overweight	Initialise
Oct 08, 2024	Wells Fargo	-	Overweight	Initialise
Oct 03, 2024	Wedbush	Neutral	Neutral	Hold
Aug 09, 2024	Bank of America Securities	Neutral	Neutral	Hold
Jul 08, 2024	Wedbush	Buy	Buy	Hold
Jul 08, 2024	Citigroup	Underperform	Underperform	Hold

Row per page

Go to

Arcus Biosciences's last stock rating was published by Citigroup on Oct 24, 2024. The company gave RCUS a "Buy" rating, the same as its previous rate.

Arcus Biosciences Financial Forecast

Arcus Biosciences Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$32.00M	$29.00M	$25.00M	$345.00K	$33.58M	$26.76M	$18.00M	$354.50M	$9.46M
Avg Forecast	$283.44M	$227.99M	$164.52M	$120.12M	$65.76M	$51.98M	$35.43M	$26.21M	$25.00M	$25.00M	$25.00M	$25.00M	$37.13M	$38.70M	$38.70M	$40.70M	$30.35M	$38.95M	$26.24M	$28.77M	$28.30M	$27.28M	$31.81M	$25.68M	$23.72M	$22.16M	$21.57M	$27.21M	$11.85M	$9.38M
High Forecast	$355.59M	$286.03M	$206.40M	$150.70M	$82.50M	$65.21M	$44.45M	$32.88M	$31.36M	$31.36M	$31.36M	$31.36M	$46.58M	$48.55M	$48.55M	$51.06M	$34.07M	$48.87M	$26.24M	$28.77M	$34.67M	$36.65M	$39.91M	$32.21M	$29.76M	$22.16M	$21.57M	$27.21M	$11.85M	$9.38M
Low Forecast	$227.67M	$183.13M	$132.14M	$96.48M	$52.82M	$41.75M	$28.46M	$21.05M	$20.08M	$20.08M	$20.08M	$20.08M	$29.82M	$31.08M	$31.08M	$32.69M	$27.62M	$31.29M	$26.24M	$28.77M	$23.83M	$22.50M	$25.55M	$20.62M	$19.05M	$22.16M	$21.57M	$27.21M	$11.85M	$9.38M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	6	3	2	2	4	9	6	4	3	7	4	3	4	7
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.17%	0.91%	0.97%	0.01%	1.52%	1.24%	0.66%	29.92%	1.01%

Arcus Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $28.30M, with a low forecast of $23.83M, and a high forecast of $34.67M. RCUS's average Quarter revenue forecast represents a -11.56% decrease compared to the company's last Quarter revenue of $32.00M (Sep 23).

Arcus Biosciences EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	6	3	2	2	4	9	6	4	3	7	4	3	4	7
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-80.00M	$-83.00M	$-77.00M	$-66.00M	$-62.82M	$-64.62M	$-65.14M	$281.00M	$-76.43M
Avg Forecast	$-217.58M	$-175.01M	$-126.29M	$-92.21M	$-50.48M	$-39.90M	$-27.20M	$-20.12M	$-19.19M	$-19.19M	$-19.19M	$-19.19M	$-28.50M	$-29.71M	$-29.71M	$-31.24M	$-23.30M	$-29.90M	$-20.14M	$-50.33M	$-21.72M	$-20.94M	$-24.42M	$-53.82M	$-18.21M	$-17.09M	$-16.64M	$-57.57M	$-9.14M	$-7.24M
High Forecast	$-174.76M	$-140.58M	$-101.44M	$-74.06M	$-40.55M	$-32.05M	$-21.85M	$-16.16M	$-15.41M	$-15.41M	$-15.41M	$-15.41M	$-22.89M	$-23.86M	$-23.86M	$-25.10M	$-21.21M	$-24.02M	$-20.14M	$-40.26M	$-18.29M	$-17.27M	$-19.62M	$-43.06M	$-14.63M	$-17.09M	$-16.64M	$-46.05M	$-9.14M	$-7.24M
Low Forecast	$-272.97M	$-219.57M	$-158.44M	$-115.68M	$-63.33M	$-50.06M	$-34.12M	$-25.24M	$-24.08M	$-24.08M	$-24.08M	$-24.08M	$-35.75M	$-37.27M	$-37.27M	$-39.20M	$-26.15M	$-37.51M	$-20.14M	$-60.39M	$-26.61M	$-28.13M	$-30.64M	$-64.59M	$-22.84M	$-17.09M	$-16.64M	$-69.08M	$-9.14M	$-7.24M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.82%	3.40%	1.43%	3.62%	3.68%	3.88%	1.13%	-30.74%	10.56%

3 analysts predict RCUS's average Quarter EBITDA for Mar 22 to be $-57.57M, with a high of $-46.05M and a low of $-69.08M. This is -120.49% lower than Arcus Biosciences's previous annual EBITDA (Dec 21) of $281.00M.

Arcus Biosciences Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	6	3	2	2	4	9	6	4	3	7	4	3	4	7
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-71.00M	$-75.00M	$-80.00M	$-67.00M	$-60.44M	$-64.28M	$-67.99M	$279.37M	$-77.97M
Avg Forecast	$11.85M	$-18.17M	$-54.05M	$-73.07M	$-95.72M	$-103.22M	$-113.85M	$-123.15M	$-119.79M	$-118.13M	$-115.57M	$-118.52M	$-112.65M	$-110.05M	$-106.57M	$-103.65M	$-109.95M	$-96.55M	$-101.91M	$-52.53M	$-93.65M	$-103.23M	$-100.39M	$-56.18M	$1.65B	$-94.60M	$-85.74M	$-60.09M	$-99.65M	$-96.31M
High Forecast	$15.78M	$-13.52M	$-40.23M	$-54.37M	$-71.24M	$-76.81M	$-84.73M	$-91.65M	$-89.15M	$-87.91M	$-86.00M	$-88.20M	$-83.83M	$-81.90M	$-79.31M	$-80.21M	$-82.46M	$-71.85M	$-75.84M	$-42.02M	$-77.33M	$-95.01M	$-74.71M	$-44.94M	$1.98B	$-94.60M	$-85.74M	$-48.07M	$-99.65M	$-96.31M
Low Forecast	$8.82M	$-24.18M	$-71.94M	$-97.25M	$-127.40M	$-137.38M	$-151.52M	$-163.91M	$-159.43M	$-157.22M	$-153.81M	$-157.74M	$-149.93M	$-146.46M	$-141.84M	$-127.08M	$-132.69M	$-128.50M	$-135.64M	$-63.04M	$-122.86M	$-112.37M	$-133.61M	$-67.42M	$1.32B	$-94.60M	$-85.74M	$-72.10M	$-99.65M	$-96.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.69%	0.75%	1.42%	-0.04%	0.64%	0.75%	1.13%	-2.80%	0.81%

Arcus Biosciences's average Quarter net income forecast for Mar 22 is $-60.09M, with a range of $-72.10M to $-48.07M. RCUS's average Quarter net income forecast represents a -121.51% decrease compared to the company's last Quarter net income of $279.37M (Dec 21).

Arcus Biosciences SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	6	3	2	2	4	9	6	4	3	7	4	3	4	7
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$30.00M	$28.00M	$30.00M	$28.00M	$26.29M	$25.84M	$23.97M	$23.30M	$16.34M
Avg Forecast	$246.38M	$198.18M	$143.01M	$104.41M	$57.16M	$45.18M	$30.80M	$22.78M	$21.73M	$21.73M	$21.73M	$21.73M	$32.27M	$33.64M	$33.64M	$35.38M	$26.38M	$33.86M	$22.81M	$18.52M	$24.60M	$23.72M	$27.65M	$19.81M	$20.62M	$19.26M	$18.75M	$21.19M	$10.30M	$8.16M
High Forecast	$309.10M	$248.63M	$179.41M	$131.00M	$71.72M	$56.68M	$38.64M	$28.58M	$27.26M	$27.26M	$27.26M	$27.26M	$40.49M	$42.20M	$42.20M	$44.38M	$29.62M	$42.48M	$22.81M	$22.23M	$30.14M	$31.85M	$34.69M	$23.77M	$25.87M	$19.26M	$18.75M	$25.42M	$10.30M	$8.16M
Low Forecast	$197.90M	$159.18M	$114.87M	$83.87M	$45.92M	$36.29M	$24.74M	$18.30M	$17.46M	$17.46M	$17.46M	$17.46M	$25.92M	$27.02M	$27.02M	$28.42M	$24.01M	$27.20M	$22.81M	$14.82M	$20.71M	$19.56M	$22.21M	$15.85M	$16.56M	$19.26M	$18.75M	$16.95M	$10.30M	$8.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26%	1.01%	1.51%	1.36%	1.37%	1.38%	1.13%	2.26%	2.00%

Arcus Biosciences's average Quarter SG&A projection for Dec 23 is $24.60M, based on 4 Wall Street analysts, with a range of $20.71M to $30.14M. The forecast indicates a -18.00% fall compared to RCUS last annual SG&A of $30.00M (Sep 23).

Arcus Biosciences EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	6	3	2	2	4	9	6	4	3	7	4	3	4	7
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.95	$-1.02	$-1.10	$-0.92	$-0.84	$-0.90	$-0.96	$3.97	$-1.11
Avg Forecast	$0.13	$-0.20	$-0.59	$-0.80	$-1.05	$-1.13	$-1.25	$-1.35	$-1.31	$-1.29	$-1.26	$-1.30	$-1.23	$-1.20	$-1.17	$-1.13	$-1.20	$-1.06	$-1.11	$-1.01	$-1.02	$-1.13	$-1.10	$-1.16	$-1.14	$-1.04	$-0.94	$-0.85	$-1.09	$-1.06
High Forecast	$0.17	$-0.15	$-0.44	$-0.59	$-0.78	$-0.84	$-0.93	$-1.00	$-0.98	$-0.96	$-0.94	$-0.96	$-0.92	$-0.90	$-0.87	$-0.88	$-0.90	$-0.79	$-0.83	$-0.75	$-0.85	$-1.04	$-0.82	$-0.87	$-0.85	$-1.04	$-0.94	$-0.85	$-1.09	$-1.06
Low Forecast	$0.10	$-0.26	$-0.79	$-1.06	$-1.39	$-1.50	$-1.66	$-1.79	$-1.74	$-1.72	$-1.68	$-1.73	$-1.64	$-1.60	$-1.55	$-1.39	$-1.45	$-1.41	$-1.48	$-1.34	$-1.34	$-1.23	$-1.46	$-1.55	$-1.52	$-1.04	$-0.94	$-0.85	$-1.09	$-1.06
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.84%	0.93%	0.95%	0.81%	0.81%	0.96%	1.12%	-3.63%	1.05%

According to 3 Wall Street analysts, Arcus Biosciences's projected average Quarter EPS for Mar 22 is $-0.85, with a low estimate of $-0.85 and a high estimate of $-0.85. This represents a -121.52% decrease compared to RCUS previous annual EPS of $3.97 (Dec 21).

Arcus Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.68	$70.00	10194.12%	Buy
XFOR	X4 Pharmaceuticals	$0.40	$3.67	817.50%	Buy
INZY	Inozyme Pharma	$3.13	$14.67	368.69%	Buy
ITOS	iTeos Therapeutics	$8.23	$37.67	357.72%	Buy
CNSP	CNS Pharmaceuticals	$0.11	$0.50	354.55%	-
IMMX	Immix Biopharma	$1.59	$7.00	340.25%	Buy
RLAY	Relay Therapeutics	$5.11	$19.40	279.65%	Buy
ABOS	Acumen Pharmaceuticals	$2.40	$7.00	191.67%	Buy
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
APLS	Apellis Pharmaceuticals	$26.27	$74.50	183.59%	Buy
TCRX	TScan Therapeutics	$4.41	$12.00	172.11%	Buy
GPCR	Structure Therapeutics	$34.17	$92.40	170.41%	Buy
ANNX	Annexon	$6.12	$14.00	128.76%	Buy
CGEM	Cullinan Oncology	$13.86	$31.50	127.27%	Buy
RCUS	Arcus Biosciences	$15.70	$33.00	110.19%	Buy
BPMC	Blueprint Medicines	$88.69	$109.71	23.70%	Buy
PTCT	PTC Therapeutics	$39.23	$46.50	18.53%	Hold
KRYS	Krystal Biotech	$170.74	$191.00	11.87%	Buy
MDGL	Madrigal Pharmaceuticals	$288.58	$315.75	9.42%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy

RCUS Forecast FAQ

Is Arcus Biosciences a good buy?

Yes, according to 7 Wall Street analysts, Arcus Biosciences (RCUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of RCUS's total ratings.

What is RCUS's price target?

Arcus Biosciences (RCUS) average price target is $33 with a range of $20 to $46, implying a 110.19% from its last price of $15.7. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arcus Biosciences stock go up soon?

According to Wall Street analysts' prediction for RCUS stock, the company can go up by 110.19% (from the last price of $15.7 to the average price target of $33), up by 192.99% based on the highest stock price target, and up by 27.39% based on the lowest stock price target.

Can Arcus Biosciences stock reach $20?

RCUS's average twelve months analyst stock price target of $33 supports the claim that Arcus Biosciences can reach $20 in the near future.

What is Arcus Biosciences's current price target trend?

2 Wall Street analysts forecast a $33 price target for Arcus Biosciences (RCUS) this month, up 110.19% from its last price of $15.7. Compared to the last 3 and 12 months, the average price target increased by 107.01% and increased by 104.65%, respectively.

What are Arcus Biosciences's analysts' financial forecasts?

Arcus Biosciences's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $179.38M (high $225.04M, low $144.08M), average EBITDA is $-138M (high $-111M, low $-173M), average net income is $-436M (high $-324M, low $-580M), average SG&A $155.93M (high $195.62M, low $125.24M), and average EPS is $-4.77 (high $-3.55, low $-6.348). RCUS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $796.07M (high $998.72M, low $639.42M), average EBITDA is $-611M (high $-491M, low $-767M), average net income is $-133M (high $-92.347M, low $-185M), average SG&A $691.98M (high $868.14M, low $555.82M), and average EPS is $-1.46 (high $-1.01, low $-2.019).

Did the RCUS's actual financial results beat the analysts' financial forecasts?

Based on Arcus Biosciences's last annual report (Dec 2022), the company's revenue was $112M, beating the average analysts forecast of $94.66M by 18.32%. Apple's EBITDA was $-264M, beating the average prediction of $-110M by 141.09%. The company's net income was $-267M, missing the average estimation of $1.41B by -118.96%. Apple's SG&A was $104M, beating the average forecast of $79.82M by 30.30%. Lastly, the company's EPS was $-4.87, beating the average prediction of $-3.973 by 22.57%. In terms of the last quarterly report (Sep 2023), Arcus Biosciences's revenue was $32M, beating the average analysts' forecast of $27.28M by 17.28%. The company's EBITDA was $-80M, beating the average prediction of $-20.944M by 281.97%. Arcus Biosciences's net income was $-71M, missing the average estimation of $-103M by -31.22%. The company's SG&A was $30M, beating the average forecast of $23.72M by 26.49%. Lastly, the company's EPS was $-0.95, missing the average prediction of $-1.129 by -15.89%